Results 1 to 10 of about 5,730 (206)

Physiologically‐based pharmacokinetic modeling for investigating the effect of simeprevir on concomitant drugs and an endogenous biomarker of OATP1B [PDF]

open access: yesCPT: Pharmacometrics & Systems Pharmacology, 2023
The orally available anti‐hepatitis C virus (HCV) drug simeprevir exhibits nonlinear pharmacokinetics at the clinical doses due to saturation of cytochrome P450 (CYP) 3A4 metabolism and organic anion transporting peptide (OATP) 1B mediated hepatic uptake.
Shinji Nakayama   +4 more
doaj   +2 more sources

Molecular Mechanisms of Resistance to Direct-Acting Antiviral (DAA) Drugs for the Treatment of Hepatitis C Virus Infections [PDF]

open access: yesDiagnostics, 2023
Hepatitis C virus (HCV) is a hepatotropic virus that affects millions of human lives worldwide. Direct-acting antiviral (DAA) regimens are the most effective HCV treatment option.
Mohammad Asrar Izhari
doaj   +2 more sources

Elongation factor Tu promotes the onset of periodontitis through mediating bacteria adhesion [PDF]

open access: yesnpj Biofilms and Microbiomes
Periodontitis, a leading cause of adult tooth loss and linked to various systemic diseases, is promoted by subgingival plaque biofilms, with Streptococci as early colonizers responsible for surface adhesion.
Leyi Xiao   +15 more
doaj   +2 more sources

Evaluation of the genetic toxicity of sofosbuvir and simeprevir with and without ribavirin in a human-derived liver cell line

open access: yesAnais da Academia Brasileira de Ciências, 2021
Direct-acting antivirals have revolutionized the treatment of chronic hepatitis C. Sofosbuvir and simeprevir are prescribed worldwide. However, there is a scarcity of information regarding their genotoxicity.
CARINA S. LIBRELOTTO   +4 more
doaj   +1 more source

Simeprevir Potently Suppresses SARS-CoV-2 Replication and Synergizes with Remdesivir

open access: yesACS Central Science, 2021
Ho Sing Lo   +2 more
exaly   +2 more sources

DAA - directly acting antivirals - as a new, more efficient solution of the chronic hepatitis C treatment and theirs various application.

open access: yesJournal of Education, Health and Sport, 2023
Introduction Cirrhosis is a condition in which the liver becomes fibrotic following damage to the liver and transforms the architecture of the organ into regenerative nodules.
Kamila Abram   +9 more
doaj   +1 more source

Possibilities of using cepeginterferon alpha-2b in double (cepeginterferon alfa-2b and ribavirin) and triple (simeprevir, cepeginterferon alpha-2b, and ribavirin) antiviral therapy regimens for chronic hepatitis C. A review of clinical trials and experience of everyday clinical practice [PDF]

open access: yesТерапевтический архив, 2016
Since the incidence of chronic hepatitis C (CHC) increases steadily, the priority of national health care is to provide antiviral therapy (AVT) for the maximum number of patients infected with hepatitis C virus (HCV).
O O Znoyko   +5 more
doaj   +1 more source

Interferon-Free Hepatitis C Treatment before and after Liver Transplantation: The Role of HCV Drug Resistance

open access: yesViruses, 2015
Hepatitis C virus (HCV) infection is one of the leading causes of end-stage liver disease and the main indication for liver transplantation (LT) in most countries.
Bruno Roche   +3 more
doaj   +1 more source

The Observed Effect of Gastric Bypass Surgery on Direct-acting Antiviral Treatment: a Case Report

open access: yesAnnals of Hepatology, 2018
Chronic hepatitis C virus (HCV) infection can be cured with treatment using direct-acting antivirals (DAAs). Although these drugs have been widely studied, information about certain special populations is missing.
Elise J. Smolders   +4 more
doaj   +1 more source

PROTEASE INHIBITOR NARLAPREVIR IN THERAPY OF HEPATITIS C VIRUS GENOTYPE 1 INFECTION IN TREATMENT-NAÏVE PATIENTS WITHOUT CIRRHOSIS: PHARMACOECONOMIC EVALUATION

open access: yesЖурнал инфектологии, 2017
The incidence of chronic hepatitis C inRussiais extremely high, that requires an increase the access to effective treatment regimens.The aim of the study is to assess the cost of HCV therapy (genotype 1) of naïve patients without cirrhosis with second ...
A. V. Rudakova   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy